Torrent Pharmaceuticals Ltd (TORNTPHARM) is currently trading at 4,804.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Torrent Pharmaceuticals is an India‑headquartered, vertically integrated pharmaceutical company focused on branded chronic and sub‑chronic therapies, with a diversified international presence across the US, Europe (Germany) and Latin America (Brazil) and over 15 country subsidiaries supporting formulation manufacturing, R&D and commercial operations for both regulated and emerging markets. In Q3 FY26 Torrent reported consolidated revenues of INR 3,303 crore, up 18% year‑on‑year, with Operating EBITDA of INR 1,088 crore and an operating margin of 32.9%. Branded markets contributed roughly 75% of revenues; India grew 14% and Brazil grew 27%, while the U.S. and Germany contributed double‑digit and modest growth respectively amid some supply constraints. Torrent acquired a controlling stake in JB Pharma in January and began line‑by‑line consolidation; management expects INR 400–450 crore of cost synergies over 2–3 years (20% in year one, majority thereafter) and a 6–9 month timeline to integrate post NCLT merger, making the JB acquisition a material near‑term strategic catalyst for the company. Brazil represents a high‑conviction growth opportunity with a prioritized Semaglutide (GLP‑1) filing; management reports ANVISA prioritization and a 60‑molecule pipeline, but cautions on unpredictable approval timing and potential pricing erosion, which could meaningfully influence Brazilian revenue upside upon launch. Near‑term operational risks include regulatory and third‑party supplier disruptions in Germany that depressed constant‑currency sales; the U.S. business is small but supported by a launch pipeline with management targeting annualized U.S. revenues near $200 million over the medium term, contingent on timely approvals and competitive dynamics.

Over the past 52 weeks, Torrent Pharmaceuticals Ltd has traded between a low of ₹3,480.00 and a high of ₹5,249.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Torrent Pharmaceuticals Ltd has a market capitalization of approximately 1,82,738.23. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Torrent Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 84.76 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,82,738.23 Cr, Torrent Pharmaceuticals Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Torrent Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Torrent Pharmaceuticals Ltd is 84.76. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Revenue rose 11% year-on-year to INR 3,178 crore, while consolidated net profit increased about 20% to INR 548 crore for the quarter ended June 2025.

Torrent Pharma said the USFDA inspected its Dahej, Gujarat facility from January 19-23, 2026 and the inspection concluded with zero observations and no Form 483 issued.

Torrent Pharmaceuticals said the amalgamation became effective on July 8, 2026, after filing certified copies of the NCLT order with the Registrar of Companies.

J.B. Pharma shareholders will receive 51 Torrent Pharma shares for every 100 J.B. Pharma shares held, as stated in the approved scheme.